Results 71 to 80 of about 465 (157)

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer. [PDF]

BMC Urol
Ikeda M, Uemura K, Ito Y, Ito H, Kawahara T, Hasumi H, Teranishi JI, Makiyama K, Uemura H.   +8 more
europepmc   +1 more source

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. [PDF]

Future Oncol
Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N.   +10 more
europepmc   +1 more source

A new polymorph of 2-thiohydantoin

A new polymorph of 2-thiohydantoin
A new polymorphic crystal of the title compound, C3H4N2OS, belongs to space group P1 with cell dimensions of a = 4.0520(9)Å, b = 6.550(1)Å, c = 9.170(2)Å, a = 100.148(4)°, b = 100.814(4)°, g = 96.831(4)°, R1= 0.069. Neighboring molecules are connected to form cyclic dimers via two types of hydrogen bonds, one between the thioamide groups and the other ...
openaire  

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. [PDF]

Int J Mol Sci
Posocco B, Pasin D, De Cesaro N, Pivetta A, Gagno S, Canil G, Cecchin E, Cecchin R, Speziani S, Dri A, Bortolus G, Spina M, Santarossa S, Puglisi F, Fratino L, Cecchin E.   +15 more
europepmc   +1 more source

Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients. [PDF]

Investig Clin Urol
Lee CH, Kim S, Ku JY, Kim KH, Kang BJ, Goh HJ, Seo WI, Ha HK.   +7 more
europepmc   +1 more source

Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. [PDF]

Eur Thyroid J
David K, Van Crombrugge P, Van der Biest AM, D'Hondt F, Claessens F, Giesen A, Joniau S, Decallonne B.   +7 more
europepmc   +1 more source

PSMA expression assessed by [¹⁸F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide. [PDF]

Cancer Imaging
Berg EK, Kunte SC, Zahner J, Holzgreve A, Aydogdu CD, Schmid HP, Eismann L, Rodler S, Unterrainer M, Werner RA, Stief CG, Unterrainer LM, Casuscelli J.   +12 more
europepmc   +1 more source

Cost-effectiveness analysis of second-generation androgen receptor antagonists for the treatment of metastatic hormone-sensitive prostate cancer. [PDF]

Front Public Health
Yang Y, Chen YQ, Huang LZ, Chen Y.
europepmc   +1 more source

Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations. [PDF]

Acta Derm Venereol
Gil-Lianes J, Amat-Samaranch V, Giavedoni P, Vilaseca A, Córdoba Sánchez J, Alamon-Reig F, Castillo P, Garcia AP, Pascal M, Carrera C.   +9 more
europepmc   +1 more source